Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids.

摘要: Glatiramer Acetate (GA) has provided safe and effective treatment for multiple sclerosis (MS) patients two decades. It acts as an antigen, yet the precise mechanism of action remains to be fully elucidated, no validated pharmacokinetic or pharmacodynamic biomarkers exist. In order better characterize GA's biological impact, genome-wide expression studies were conducted with a human monocyte (THP-1) cell line. Consistent previous literature, branded GA upregulated anti-inflammatory markers (e.g. IL10), modulated immune-related pathways. Despite some similarities, significant differences observed between profiles induced by Probioglat, differently-manufactured glatiramoid purported generic GA. Key results verified using qRT-PCR. Genes CCL5, adj. p < 4.1 × 10(-5)) critically involved in pro-inflammatory pathways response lipopolysaccharide, = 8.7 10(-4)) significantly Probioglat compared genes also tested confirmed at protein level, primary monocytes. These observations suggest differential impact glatiramoids warrant further investigation.